Influence of different doses of trospium and solifenacin on manageability of OAB symptoms with different severity in elderly men and women

Abstract

Objective:

We studied the rationale for using standard and increased dosages of solifenacin and trospium against overactive bladder (OAB) symptoms of different severity among elderly patients.

Methods:

A total of 327 patients took part in the study: 199 women and 128 men older than 65 years (median age 69.1). The state of the lower urinary tracts was estimated by cystometry, ICIQ-SF and bladder diaries. Frequency of urgency urinary incontinence (UUI) was taken as a criterion of OAB symptom severity.

Result:

Administration of double-dosed trospium and solifenacin leads to decrease of frequency of UUI both in the group with severe symptoms (B¹: 6.1 (0.5) →2.4 (0.9), p ⩽ 0.05), and in the group with moderate symptoms of OAB (A¹: 2.8 (0.8) →0.5 (0.4), p ⩽ 0.001). Under a combination of trospium and solifenacin in doses recommended by manufacturers, UUI decreased authentically in the group with moderate symptoms (A²: 2.9 (0.5) →0.9 (0.5), p ⩽ 0.05) and unauthentically in the group with severe symptoms of detrusor dysfunction (B²: 7.0 (1.2) → 4.3 (1.5), p ⩾ 0.05).

During the experiment six patients (1.8%) elected not to participate because of intolerable adverse events. Forty-seven more individuals (14.4%) felt adverse effects, among which the most frequent were: xerostomia (15 patients or 4.6%), faintness (nine patients or 3.8%), dryness of integuments (six patients or 1.8%).

Conclusion:

A standard-dose combination of solifenacin and trospium in older patients with moderate symptoms of OAB enables a good therapeutic effect in a short time without increasing risk of side effects. High therapeutic doses of antimuscarinic drugs are reasonable for older men and women with severe symptoms of OAB.

Increasing the dose of simultaneous use of solifenacin and trospium yields a good therapeutic effect to correct UUI; however, it raises the hazard of appearance of adverse effects.

The number of side effects in the group of elderly individuals who were taking the combination of increased and standard dosages of solifenacin and trospium does not significantly differ.

Keywords

Solifenacin trospium overactive bladder older

Get full access to this article

View all access options for this article.

References

Kurita

Yamazaki

Fukumori

. Overactive bladder symptom severity is associated with falls in community-dwelling adults: LOHAS study. BMJ Open 2013; 3: e002413.

Milsom

Coyne

Nicholson

. Global prevalence and economic burden of urgency urinary incontinence: A systematic review. Eur Urol 2014; 65: 79–95.

Natalin

Lorenzetti

Dambros

Management of OAB in those over age 65. Curr Urol Rep 2013; 14: 379–385.

de Ridder

Roumeguère

Kaufman

. Overactive bladder symptoms, stress urinary incontinence and associated bother in women aged 40 and above; a Belgian epidemiological survey. Int J Clin Pract 2013; 67: 198–204.

Kirss

Lang

Toompere

. Prevalence and risk factors of urinary incontinence among Estonian postmenopausal women. Springerplus 2013; 2: 524.

Patrick

Khalaf

Dmochowski

. Psychometric performance of the incontinence quality-of-life questionnaire among patients with overactive bladder and urinary incontinence. Clin Ther 2013; 35: 836–845.

Espuña-Pons

Castro-Díaz

Díaz-Cuervo

. Impact of overactive bladder treatment on the quality of life of patients over 60 with associated pathologies [article in English, Spanish]. Arch Esp Urol 2013; 66: 287–294.

Heesakkers

Cruz

Igawa

. Overactive bladder: Pathophysiology, diagnostics, and therapies. Adv Urol 2011; 2011: 863504.

Griebling

TL.

Overactive bladder in elderly men: Epidemiology, evaluation, clinical effects, and management. Curr Urol Rep 2013; 14: 418–425.

10.

Wagg

Cardozo

Chapple

. Overactive bladder syndrome in older people. BJU Int 2007; 99: 502–509.

11.

Andersson

KE.

New developments in the management of overactive bladder: Focus on mirabegron and onabotulinumtoxinA. Ther Clin Risk Manag 2013; 9: 161–170.

12.

Murphy

Krlin

Goldman

HB.

Treatment of overactive bladder: What is on the horizon?

Int Urogynecol J 2013; 24: 5–13.

13.

Erdem

Chu

Management of overactive bladder disease and urge urinary incontinence in the elderly patient. Am J Med 2006; 119: 29–36.

14.

Gupta

Kaushal

Medical treatment of overactive bladder: An overview. Curr Clin Pharmacol 2012; 7: 229–239.

15.

Andersson

KE.

Antimuscarinics for treatment of overactive bladder. Lancet Neurol 2004; 3: 46–53.

16.

Oefelein

MG.

Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder. Drug Saf 2011; 34: 733–754.

17.

Nichol

. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid program. Value Health 2005; 8: 495–505.

18.

Bödeker

Madersbacher

Neumeister

. Dose escalation improves therapeutic outcome: Post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence. BMC Urol 2010; 10: 15.

19.

Chun

Song

Han

. Clinical factors associated with dose escalation of solifenacin for the treatment of overactive bladder in real life practice. Int Neurourol J 2014; 18: 23–30.

20.

Ikeda

Kobayashi

Suzuki

. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol 2002; 366: 97–103.

21.

Ohtake

Ukai

Hatanaka

. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur J Pharmacol 2004; 492: 243–250.

22.

Pak

Petrou

Staskin

DR.

Trospium chloride: A quaternary amine with unique pharmacologic properties. Curr Urol Rep 2003; 4: 436–440.

23.

Jeong

Chung

. Efficacy and tolerability of combined medication of two different antimuscarinics for treatment of adults with idiopathic overactive bladder in whom a single agent antimuscarinic therapy failed. Can Urol Assoc J 2013; 7: E88–E92.

24.

Amend

Hennenlotter

Schäfer

. Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol 2008; 53: 1021–1028.

25.

Nardulli

Losavio

Ranieri

. Combined antimuscarinics for treatment of neurogenic overactive bladder. Int J Immunopathol Pharmacol 2012; 25 (1 Suppl): 35S–41S.

26.

Diokno

Lee

Zorn

. Factors associated with clinical assessment of overactive bladder and selection of treatment. Clin Ther 2001; 23: 1542–1551.

27.

Kosilov

Loparev

Ivanovskaya

. Management of overactive bladder (OAB) in elderly men and women with combined, high-dosed antimuscarinics without increased side effects. UroToday Int J 2013; 6: art 47.

28.

Kosilov

Loparev

Ivanovskaya

. Maintenance of the therapeutic effect of two high-dosage antimuscarinics in the management of overactive bladder in elderly women. Int Neurourol J 2013; 17: 191–196.

29.

Kosilov

Loparev

Ivanovskaya

. Effectiveness of combined high-dosed trospium and solifenacin depending on severity of OAB symptoms in elderly men and women under cyclic therapy. Cent European J Urol 2014; 67: 43–48.

30.

Thüroff

Abrams

Andersson

. EAU guidelines on urinary incontinence. Eur Urol 2011; 59: 387–400.

31.

Singh

Lucas

Dolan

. Minimum standards for urodynamic practice in the UK. Neurol Urodyn 2010; 29: 1365–1372.

32.

Schafer

Abrams

Liao

. Good urodynamic practices: Uroflowmetry, filling cystometry, and pressure-flow studies. Neurol Urodyn 2002; 21: 261–274.

33.

Khandelwal

Kistler

Diagnosis of urinary incontinence. Am Fam Physician 2013; 87: 543–50.

34.

Gomes

Arap

Trigo-Rocha

FE.

Voiding dysfunction and urodynamic abnormalities in elderly patients. Rev Hosp Clín Fac Med Sao Paulo 2004; 59: 206–215.

35.

Tissot

Amundsen

Diokno

. Bladder diary measurements in asymptomatic males: Frequency, volume per void, and 24-hr volume. Neurourol Urodyn 2008; 27: 198–204.

36.

Parsons

Amundsen

Cardozo

. Bladder diary patterns in detrusor overactivity and urodynamic stress incontinence. Neurourol Urodyn 2007; 26: 800–806.

37.

Amundsen

Parsons

Cardozo

. Bladder diary volume per void measurements in detrusor overactivity. J Urol 2006; 176 (6 Pt 1): 2530–2534.

38.

Fulton

Amundsen

. Patient preferences for different severities of and treatments for overactive bladder. Female Pelvic Med Reconstr Surg 2011; 17: 184–189.

39.

Dmochowski

Larson-Peters

Aronstein

. Efficacy of darifenacin in patients with varying baseline symptom severity. UroToday Int J 2009; 2: 3.

40.

Coyne

Matza

Kopp

. The validation of the patient perception of bladder condition (PPBC): A single-item global measure for patients with overactive bladder. Eur Urol 2006; 49: 1079–1086.

41.

Andersson

KE.

Muscarinic acetylcholine receptors in the urinary tract. Handb Exp Pharmacol 2011; 202: 319–344.

42.

Korstanje

Krauwinkel

Specific pharmacokinetic aspects of the urinary tract. Handb Exp Pharmacol 2011; 202: 267–282.

43.

Kanai

AJ.

Afferent mechanism in the urinary tract. Handb Exp Pharmacol 2011; 202: 171–205.

44.

Chapple

Khullar

Gabriel

. The effects of antimuscarinic treatments in overactive bladder, an update of a systematic review and meta-analysis. Eur Urol 2008; 54: 543–562.

45.

Giannitsas

Athanasopoulos

Male overactive bladder: Pharmacotherapy for the male. Curr Opin Urol 2013; 23: 515–519.

46.

Igawa

Aizawa

Homma

Beta3-adrenoceptor agonists: Possible role in the treatment of overactive bladder. Korean J Urol 2010; 51: 811–818.

47.

Yoshida

Miyamae

Iwashita

. Management detrusor dysfunction in the elderly: Changes in acetylcholine and adenosine triphosphate release during aging. Urology 2004; 63 (Suppl 1): 17–23.